CombiMatrix Stock Slides 10 Percent on Q2 Revenue Decline | GenomeWeb
NEW YORK (GenomeWeb News) - Shares in CombiMatrix were down 10 percent, or $.14, at $1.22 in mid-afternoon trading today after the company reported a decline in revenues for the second quarter.
 
As GenomeWeb News reported today, total revenues declined 3.5 percent to $1.79 million, though revenues from product sales more than doubled.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: flu susceptibility and Y chromosome variation in mice, deletion tied to epilepsy in dog breed, and more.

Sequencing is enabling the roots of some rare diseases to be determined, the Financial Times reports.

Proove Biosciences had allegedly been paying doctors to perform its opioid risk and other genetic tests, Stat News reports.

A floated budget plan could see non-military discretionary spending in the US — which includes science agency funding — fall, the New York Times reports.